Loading...
NPI 1265199590 · Skokie, IL · Clinical Medical Laboratory
Customize your policy alerts
Get alerted when relevant policies change without checking for updates manually.
Monitor payer policy activity
Medtech Lab LLC is a clinical medical laboratory provider located in Skokie, Illinois. This profile covers 1 Medicare and 4 Medicaid CPT/HCPCS procedure codes, with claims volume, average reimbursement, and total revenue by code, benchmarked against other providers billing the same services.
Provider details (source: NPPES NPI Registry)
| Field | Value |
|---|---|
| Entity Type | Organization |
| Organization | Medtech Lab LLC |
| Address | 3706 Dempster St |
| City | Skokie |
| State | IL |
| ZIP | 60076 |
| Taxonomy | Clinical Medical Laboratory |
| NPI Enumerated | November 22, 2021 |
Lifetime revenue by payer source (source: CMS Medicare & Medicaid claims data)
| Payer Source | Total Paid |
|---|---|
| Medicare | $10.3M |
| Medicaid | $1.3K |
MEDTECH LAB LLC is registered as a Clinical Medical Laboratory and its Medicare and Medicaid billing mix is overwhelmingly tied to COVID-19 testing services; the Medicare record shows K1034 (provision of nonprescription self‑administered COVID-19 test) with 858.9K claims and $12 avg paid/claim driving $10.3M in Medicare revenue, which aligns with a lab operation focused on high-volume distribution or provisioning of OTC COVID tests rather than a broad panel of clinical assays. The presence of high claim volume for a single COVID testing code suggests this entity operates at scale for that specific service line.
Revenue concentration is extreme on both payers: the precomputed top 3 Medicare codes account for 100.0% of this provider's total Medicare revenue, and the precomputed top 3 Medicaid codes account for 100.0% of its total Medicaid revenue. In practice the Medicare side is fully concentrated in K1034 ($10.3M), and the Medicaid side is likewise concentrated in K1034 ($1.3K), indicating virtually no diversification across other billing codes.
The provider’s overall payer mix is effectively Medicare-dominant: reported lifetime Medicare revenue is $10.3M versus lifetime Medicaid revenue of $1.3K, so Medicaid activity is negligible in scale compared with Medicare. Analysts should treat MEDTECH LAB LLC as a primarily Medicare-facing, single-service-line provider in commercial terms rather than a balanced dual-payer laboratory.
MEDTECH LAB LLC’s Medicare competitive standing for K1034 is extraordinary: it ranks #51 of 30143 providers nationally (100th percentile; extreme outlier), which indicates far-above-typical national volume for this specific code and a rare position among peers for OTC COVID test provisioning billed to Medicare. This rank signals the provider is a major national participant for K1034 relative to other billers.
By contrast, the provider’s Medicaid footprint is modest and unremarkable: K1034 on Medicaid shows 1.3K claims, $1 avg paid/claim and $1.3K revenue, ranking #22 of 59 in-state (64th percentile; typical, unremarkable volume). Other listed Medicaid codes (U0003, U0005, G2023) show nonzero claim counts (each ~181–183 claims) but $0 reported Medicaid revenue and percentile ranks in the typical range, underscoring that Medicaid billing contributes almost no paid revenue.
The provider’s NPI was enumerated on 2021-11-22 (~5 years ago), indicating relatively recent entry into the Medicare/Medicaid billing universe. Given the short tenure combined with very high Medicare K1034 volume, the organization appears to have rapidly scaled activity in its focused service line since enumeration.
Statistical standing labels in the data are consistent across payers: Medicare K1034 is explicitly noted as an "extreme outlier," which the claims and rank support, while the Medicaid code-level notes describe volumes as "typical, unremarkable" for in-state peers. Analysts should interpret the Medicare outlier designation as a sign of unusually large, code-specific market share rather than as a general statement about all services provided by the laboratory.
From a monitoring and contracting perspective, the provider’s business and revenue risk is concentrated in one code and one payer; because K1034 accounts for the entirety of reported Medicare revenue and all reported Medicaid revenue is minimal, payers and network managers should treat MEDTECH LAB LLC as a specialized COVID-test fulfillment entity and prioritize oversight, contract terms, and reimbursement arrangements specific to K1034 rather than pursuing broad laboratory fee-schedule negotiations.
Medicare revenue breakdown by CPT/HCPCS procedure code.
View: Bar Chart1 / 2
The CPT/HCPCS codes generating the most Medicare revenue for this provider.
1 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 858,870 | $10 | $10.3M |
How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 1 CPT/HCPCS codes.
View: State1 / 2
Full comparison — all codes billed, vs. state median
1 rows
| CPT/HCPCS Code | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|
| K1034 | 19 | 1,150 | 720 | $10 | $414.9K |
Medicaid revenue breakdown by year and by CPT/HCPCS procedure code, including monthly billing trends and the top codes driving revenue.
View: By Year1 / 3
Every CPT/HCPCS code this provider has billed to Medicaid, with claims volume, average payment, and total revenue.
4 rows
| CPT/HCPCS Code | Description | Claims | Avg Paid | Revenue |
|---|---|---|---|---|
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 1,280 | $1 | $1.3K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 180 | $0 | $0 |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 180 | $0 | $0 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 180 | $0 | $0 |
How this provider's Medicaid billing volume and revenue compare to other Illinois providers billing the same CPT/HCPCS codes.
Full comparison — all codes billed, vs. Illinois median
4 rows
| CPT/HCPCS Code | Description | Rank | Provider Count | Median Claims | Avg Paid | Average Revenue |
|---|---|---|---|---|---|---|
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high… | 210 | 350 | 400 | $70 | $514.7K |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc,… | 137 | 210 | 680 | $20 | $206.4K |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 265 | 400 | 550 | $20 | $90.8K |
| K1034 | Provision of covid-19 test, nonprescription self-administered and self-collected use, fda approved, authorized or cleared, one test count | 22 | 60 | 660 | $1 | $3.2K |
Other providers in the same ZIP code as Medtech Lab LLC, ranked by combined Medicare and Medicaid revenue.
Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.